MedCap AB (publ) (STO:MCAP)
Sweden · Delayed Price · Currency is SEK 556.50
+7.50 (1.37%)
Jul 24, 2026, 5:29 PM CET
MedCap AB Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,319 | 2,151 | 1,856 | 1,615 | 1,154 | 949.6 |
Revenue Growth | 18.96% | 15.91% | 14.94% | 39.89% | 21.54% | 12.47% |
Gross Profit Gross Profit Growth | 1,374 | 1,257 | 1,092 | 943.1 | 707.3 | 591.9 |
Operating Income Operating Income Growth | 345.5 | 302.9 | 272.3 | 227.5 | 170.9 | 127 |
Net Income Net Income Growth | 240.8 | 219.8 | 207.4 | 172.2 | 117.6 | 96.5 |
Earnings Per Share EPS Growth | 16.00 | 14.70 | 14.00 | 11.60 | 7.90 | 6.50 |
EPS Growth | 20.30% | 5.00% | 20.69% | 46.84% | 21.54% | 54.76% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Assistive Tech Assistive Tech Growth | 1,047 | 981.8 | 767.2 | 590.5 | 270 | - |
Medtech Medtech Growth | 722.6 | 689.6 | 607.7 | 511.7 | 444.3 | - |
Specialty Pharma Specialty Pharma Growth | 486.2 | 436.6 | 431.8 | 485.3 | 397 | 316.8 |
Revenue (Total) Revenue (Total) Growth | 2,319 | 2,151 | 1,856 | 1,615 | 1,154 | 949.6 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 286.3 | 370.4 | 370.1 | 188.2 | 236.2 | 139.7 |
Total Debt Total Debt Growth | 457.6 | 482.9 | 358 | 261.2 | 340 | 256.9 |
Net Cash (Debt) Net Cash Growth | -171.3 | -112.5 | 12.1 | -73 | -103.8 | -117.2 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -11.42 | -7.50 | 0.81 | -4.91 | -7.01 | -7.92 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 387.8 | 342.7 | 360 | 228 | 85.5 | 116.3 |
Capital Expenditures CapEx Growth | -24 | -25.7 | -41.7 | -22.1 | -26.3 | -45.3 |
Free Cash Flow Free Cash Flow Growth | 363.8 | 317 | 318.3 | 205.9 | 59.2 | 71 |
Free Cash Flow Growth | 21.96% | -0.41% | 54.59% | 247.80% | -16.62% | -31.93% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 59.25% | 58.45% | 58.87% | 58.41% | 61.29% | 62.33% |
Operating Margin | 14.90% | 14.08% | 14.67% | 14.09% | 14.81% | 13.37% |
Pretax Margin | 13.53% | 13.44% | 14.10% | 13.77% | 13.17% | 12.31% |
Profit Margin | 10.41% | 10.26% | 11.28% | 10.68% | 10.22% | 10.32% |
FCF Margin | 15.69% | 14.74% | 17.15% | 12.75% | 5.13% | 7.48% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.64 | 37.35 | 42.93 | 29.09 | 27.41 | 27.38 |
Forward PE | 25.17 | 31.55 | 39.28 | 25.95 | 25.95 | 25.95 |
P/FCF Ratio | 22.93 | 26.01 | 28.27 | 24.27 | 54.15 | 37.12 |
PS Ratio | 3.69 | 3.83 | 4.85 | 3.10 | 2.78 | 2.78 |